[Disorders of water and electrolyte equilibrium in liver diseases. Part 3: therapy (author's transl)].
D001201:Ascites / Q000188:drug therapy / Q000209:etiology; D001581:Benzothiadiazines; D002191:Canrenoic Acid / Q000627:therapeutic use; D004232:Diuretics; D006801:Humans; D006929:Hyperaldosteronism / Q000517:prevention & control; D008107:Liver Diseases / Q000150:complications*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use*; D014883:Water-Electrolyte Imbalance / Q000188:drug therapy* / Q000209:etiology
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D002191:Canrenoic Acid
Störungen des Wasser-und Salzhaushaltes bei Lebererkrankungen. 3. Teil: Therapie.